These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36696174)

  • 1. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
    Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
    Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 3. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
    Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
    Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
    Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo comparative study of a novel
    Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
    Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
    [No Abstract]   [Full Text] [Related]  

  • 10. Preparation of
    Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
    Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M
    J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and characterization of a novel
    Sui Y; Duan X; Zhang J; Chu Y; Yang X
    Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
    Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
    Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
    Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
    Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
    Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
    Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.